Results 91 to 100 of about 5,420 (200)

In vitro antibacterial activity of antiretroviral drugs on key commensal bacteria from the human microbiota

open access: yesFrontiers in Cellular and Infection Microbiology
IntroductionAntiretroviral therapy has improved life expectancy in HIV-infected patients. However, people living with HIV under antiretroviral therapy are at higher risks of developing chronic complications and acquiring multidrug resistant bacteria than
Elisa Rubio-Garcia   +21 more
doaj   +1 more source

Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.

open access: yesThe Lancet HIV, 2019
BACKGROUND Current treatment for HIV-infected individuals with renal failure on haemodialysis frequently requires complex regimens with multiple pills. A daily single-tablet regimen of coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir ...
J. Eron   +16 more
semanticscholar   +1 more source

Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection

open access: yesTherapeutics and Clinical Risk Management, 2009
Christine Katlama, Robert MurphyPierre et Marie Curie Université – Paris 6, Service de Maladies Infectieuses et Tropicales, Paris, FranceAbstract: Integrase is an essential HIV-1-specific enzyme that is an active target for ...
Christine Katlama, Robert Murphy
doaj  

Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors.

open access: yesPLoS ONE, 2013
Most studies describing phenotypic resistance to integrase strand transfer inhibitors have analyzed viruses carrying only patient-derived HIV-1 integrase genes (INT-recombinant viruses).
Jan Weber   +7 more
doaj   +1 more source

Integrase inhibitor drugs during pregnancy and congenital anomalies: A case/non‐case study from the global pharmacovigilance database VigiBase®

open access: yesPharmacology Research & Perspectives
In 2018, a significant neural tube defects (NTD) signal was reported after pre‐conceptional exposure to dolutegravir, but was not confirmed in further analysis.
Laura Saint‐Lary   +3 more
doaj   +1 more source

Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS

open access: yesPatient Preference and Adherence, 2015
Roberta Prinapori,1 Antonio Di Biagio2 1Infectious Diseases, University of Genoa, Genoa, Italy; 2Unit of Infectious Diseases, IRCCS AOU San Martino-IST, Genoa, Italy Abstract: The fixed-dose combination (FDC) elvitegravir/cobicistat/emtricitabine ...
Prinapori R, Di Biagio A
doaj  

Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV

open access: yesDrug Design, Development and Therapy, 2015
Christopher E Kandel,1 Sharon L Walmsley1,21Department of Medicine, University of Toronto, Toronto, ON, Canada; 2Division of Infectious Diseases, University Health Network, Toronto, ON, CanadaAbstract: Dolutegravir is the newest integrase strand transfer
Kandel CE, Walmsley SL
doaj  

A robust pH-based second-order spectrophotometric method for the analysis of four anti-HIV drugs in pharmaceutical formulations

open access: yesScientific Reports
A robust pH-based second-order spectrophotometric strategy combined with parallel factor analysis (PARAFAC) was developed for the simultaneous determination of elvitegravir (EVG), cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (
S. Noroozi Eshlaqi   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy